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Background: Thyroid cancer is the most common endocrine-related cancer in the United States and its incidence
is rising rapidly. Since among various genetic lesions identified in thyroid cancer, the BRAFV600E mutation is found
in 50% of papillary thyroid cancers and 25% of anaplastic thyroid cancers, this mutation provides an opportunity for
targeted drug therapy. Our laboratory evaluated cellular phenotypic effects in response to treatment with PLX4032,
a BRAFV600E-specific inhibitor, in normal BRAF-wild-type thyroid cells and in BRAFV600E-positive papillary thyroid
cancer cells.
Methods: Normal BRAF-wild-type thyroid cells and BRAFV600E-mutated papillary thyroid cancer cells were
subjected to proliferation assays and analyzed for cell death by immunofluorescence. Cell cycle status was
determined using an EdU uptake assay followed by laser scanning cytometry. In addition, expression of proteins
within the MAPK signal transduction pathway was analyzed by Western blot.
Results: PLX4032 has potent anti-proliferative effects selectively in BRAF-mutated thyroid cancer cells. These effects
appear to be mediated by the drug’s activity of inhibiting phosphorylation of signaling molecules downstream of
BRAF within the pro-survival MAPK pathway. Interestingly, PLX4032 promotes the phosphorylation of these signaling
molecules in BRAF-wild-type thyroid cells.
Conclusions: These findings support further evaluation of combinational therapy that includes BRAFV600E
inhibitors in thyroid cancer patients harboring the BRAFV600E mutation.
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Thyroid cancer is the most common endocrine-related
cancer in the United States. Its incidence has been rising
for the past few decades and is predicted to double by
2019 [1-3]. Based on morphological variation, thyroid can-
cer can be classified as papillary, follicular, medullary or
anaplastic. Papillary thyroid cancer (PTC) accounts for
over 80% of all thyroid carcinoma. Most of the thyroid
cancers are believed to originate in single cells due to mu-
tations that confer growth advantages including increased
proliferation, impaired apoptosis, enhanced angiogenesis,
invasion and metastasis. Specifically, mutations causing* Correspondence: Raj_Tiwari@nymc.edu
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unless otherwise stated.over-activation of the mitogen-activated protein kinase
(MAPK) signaling pathway are found in more than 70% of
papillary thyroid cancers and include BRAF oncogene
activation, RAS mutations and RET proto-oncogene re-
arrangement [4]. Among these mutations, a single point
mutation involving substitution of glutamate for valine at
nucleotide 600 and resulting in mutant BRAF protein
(BRAFV600E) is most common. BRAF gene encodes a
MEK activator within the MAPK pathway, and it is
through aberrant protein signaling that genetic mutation
in the BRAF gene leads to PTC in more than one-third of
all cases [5-8].
Treatment of thyroid cancer, although dependent on the
stage and type of cancer, usually involves complete or par-
tial thyroidectomy, radioactive iodine (I131) therapy, and
hormone replacement therapy. Despite available treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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current thyroid cancer at least once in their lifetime. In
addition, a small subset of patients develop advanced,
metastatic disease and face limited treatment options after
traditional therapy fails, demonstrating the need for the-
rapeutic advances. As a potential therapeutic target, the
BRAF mutation plays a central role in promoting aggres-
sive phenotype of thyroid cancer and is associated with
worse prognosis. Mutation in BRAF correlates with ad-
vanced stage, lymph node metastasis, extrathyroidal ex-
tension, as well as resistance to traditional radioiodine
therapy in papillary thyroid cancer [9,10]. Guerra et al.
found that greater percentages of BRAFV600E alleles
within papillary thyroid tumors resulted in poorer disease
outcome [11]. In addition, BRAFV600E mutation has re-
cently been correlated with significantly increased cancer-
related mortality, as mortality was 5.3% in patients positive
for the BRAF mutation and only 1.1% in those without
the mutation [12].
As a serine-threonine protein kinase, BRAF plays an im-
portant role within the MAPK signaling pathway. Normal
activation of this well-studied pathway involves growth
factors binding to a variety of cellular receptors including
Receptor Tyrosine Kinases (RTKs) followed by activation
of small G protein, RAS [13]. RAS recruits proteins to the
membrane to cause activation of RAF, which in turn
phosphorylates MEK. In cascade –like fashion, MEK
phosphorylates ERK (MAPK), a kinase with over 160
downstream targets regulating diverse cellular processes
such as growth, cell cycle, differentiation, survival, and
apoptosis [13]. Out of three RAF isoforms (ARAF, BRAF,
and CRAF), BRAF is the most potent contributor to
the MAPK pathway and is the only isoform commonly
mutated in human cancer [14]. BRAFV600E mutation dis-
rupts hydrophobic interactions within the BRAF protein,
allowing for a catalytically active conformation which con-
tinuously phosphorylates MEK, independent of upstream
signals [15]. This specific genetic mutation leading to
excessive activation of the MAPK pathway accounts for
90% of all cancer-related BRAF mutations and is found in
about half of all papillary thyroid cancers and one fourth
of anaplastic thyroid malignancies [12,15]. High pre-
valence of genetic mutations causing altered signaling
pathways in human cancer has spurred development of
targeted drug therapy focusing on inhibition of intracel-
lular kinases such as mutated BRAF, which is also com-
monly found in melanoma, ovarian, and colorectal
cancers [15].
This targeted drug therapy program identified PLX4032
(Vemurafenib), a small molecule inhibitor which selec-
tively binds to the ATP binding pocket of mutated
BRAFV600E, inhibiting its ability to signal within the
MAPK pathway. One of the drug’s most appealing charac-
teristics is its selectivity towards BRAFV600E-positivetumors. Theoretically, mutated cancer cells are highly
dependent on BRAF signaling and are unable to survive
treatment while cells expressing only wild-type BRAF re-
main unaffected. Potent anti-tumor activity of PLX4032
was demonstrated in BRAFV600E-positive malignant mel-
anoma patients, as the majority of these patients ex-
perienced partial or complete tumor regression [16]. In
melanoma studies, PLX4032 treatment reduced relative
risk of death by 63% and relative risk of death or disease
progression by 74% compared to standard treatment with
dacarbazine [17]. Clinical studies involving PLX4032 and
thyroid cancer are currently underway. In a Phase I trial,
PLX4032 treatment led to partial reduction of tumor
size in one patient out of three with metastatic papillary
thyroid cancer [18]. Interestingly, it was discovered that
PLX4032 acts to promote MAPK signaling in BRAF-wild-
type cells by binding to one protomer in a RAF dimer and
transactivating the other protomer after upstream RAS
signaling [19-21]. This phenomenon may account for side
effects of the drug, including promotion of squamous cell
carcinoma.
In this study, we explore how inhibition of BRAFV600E
leads to phenotypic changes in thyroid cells and demon-
strate the selectivity of PLX4032-mediated inhibition in
thyroid cells. Although the study is limited to one papil-
lary thyroid cancer cell line and is not representative of all
thyroid cancer cell lines harboring the BRAFV600E muta-
tion, we present findings which characterize the inter-
action between a commonly mutated signal transduction
molecule and a specific inhibitor.
Methods
Cell culture
Two thyroid cell lines in this study include a human nor-
mal transformed line (Nthy-ori 3–1) and a human pa-
pillary thyroid cancer cell line (BCPAP). Dr. Norman L.
Eberhardt (Mayo Clinic, Rochester, MN) generously gifted
the Nthy-ori 3–1 cell line and BCPAP was purchased from
DSMZ in Braunschh, Germany. Both Nthy-ori 3–1 and
BCPAP were cultured in Roswell Park Memorial Institute
(RPMI)-1640 (Mediatech, Hemdon, VA) supplemented
with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA), penicillin 10,000 IU/mL, streptomycin
10,000 μg/mL (Mediatech), and 2 mM L-glutamine
(Mediatech).
XTT cell proliferation assay
Five thousand cells in 200 μL medium per well were
plated onto a 96-well plate for each cell line and allowed
to adhere overnight. Complete media in each well was
replaced with 200 μLmedia containing 5% charcoal
dextran-treated FBS and PLX4032 at concentrations of
0 μM, .5 μM, 1 μM, 5 μM, 10 μM, 20 μM, and 50 μM.
Plates were incubated at 37°C for 48 hours. After
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(plus 5 μL/mL phenazinemethosulfate) and 50 μL per well.
Plates were read at 450 nm and a reference of 630 nm.
Mean OD values for each concentration of PLX4032 were
plotted and used to calculate percent survival compared
to the untreated control. IC50 value is the concentration
corresponding to fifty percent survival.
Trypan blue exclusion assay
Nthy-ori 3–1 and BCPAP cells were harvested using
0.25% trypsin and plated in six-well culture plates at
500,000 cells in 2 mL media per well. Cells were allowed
to adhere overnight and then starved for 24 hours by
replacing complete media with phenol-red-free RPMI
containing 5% charcoal dextran-treated FBS. Cells were
left untreated or treated with 10 μM PLX4032 for 12,
24, and 36 hours. At the end of each time exposure, cells
were harvested using 0.25% trypsin and stained with
0.4% trypan blue solution (Sigma). Numbers of cells un-
able to take up stain were counted as viable cells.
Immunofluorescence staining
Nthy-ori 3–1 and BCPAP cells were harvested and seeded
onto eight-well chamber slides at a density of 10,000 cells
in 250 μl per well. Cells were allowed to adhere overnight
and then starved for 24 hours by replacing complete
media with phenol-red-free RPMI containing 5% charcoal
dextran-treated FBS. Cells were left untreated or treated
with 10 μM PLX4032 for 36 hours. Adherent cells were
stained with FITC-Annexin V, Ethidium Homodimer III
and Hoechst 33342 according to experimental procedures
of the Apoptotic/Necrotic/Healthy Cells Detection Kit
(PromoKine, Germany). Images were captured using
Axiovision Rel 4.8 on the Axiovert 200 M microscope
(Carl Zeiss MicroImaging Inc., Thornwood, NY).
EdU flow cytometry assay
Cells were harvested and seeded onto eight-well cham-
ber slides at a density of 10,000 cells in 250 μl per well.
As described earlier, cells were allowed to adhere to
slides overnight and then starved for 24 hours in
phenol-red-free RPMI containing 5% charcoal dextran-
treated FBS. Cells were left untreated or treated with
10 μM PLX4032 for 36 hours. Cells were incubated with
20 μM Click-It™ EdU (Click-iT™ EdU Flow Cytometry
Assay Kit from Invitrogen) for one hour at 37°C. Cells
were then fixed using 4% paraformaldehyde for ten mi-
nutes at room temperature and then permeabilized using
0.2% Triton-X for ten minutes at room temperature.
The Click-It™ reaction cocktail was used to detect EdU
according to Invitrogen protocol, using Alexa Fluor 488
dye. Cells were also stained with DAPI for 15 minutes at
room temperature. Intensity of maximal pixel and inte-
grated fluorescence of detected EdU was measured byLaser Scanning Cytometry (LCS) (iCys; CompuCyte,
Westwood, MA) [22].
Western blot analysis
Nthy-ori 3–1 and BCPAP cells were allowed to grow until
70% confluence. Complete media was replaced with 5%
charcoal dextran-treated FBS-containing media for 24 hours
and cells were treated with 5 μM and 10 μM PLX4032 for
24 hours. Cell samples were subjected to radioimmuno-
precipitation assay buffer (50mM Tris–HCl [pH 7.4],
150mM NaCl, 0.2% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS], 0.5% NP40, and μM Pefabloc) and
vortexed every 5 minutes for 30 minutes over ice. Whole
cell lysates were centrifuged at 14,000 rpm for 30 minutes
at 4°C. Supernatants were collected and volumes con-
taining 10 μg protein per sample were used for 12% SDS-
polyacrylamide gel electrophoresis as in our prior studies
[23,24]. Proteins on gels were transferred to Immobilon-P
membranes using 220 mA for 2 hours in a transfer cham-
ber. Membranes were blocked using 5% powdered milk in
TBST (10 mM Tris–HCl, pH 7.5, 200 mM NaCl, 0.05%
Tween-20) for 2 hours on a shaker at room temperature.
Membranes were incubated overnight in primary anti-
bodies including MEK1/2, phospho-MEK1/2, p44/42
MAPK (Erk1/2), phopho-p44/42 MAPK (Erk1/2), mTOR,
and phopho-mTOR (Cell Signaling Technology). After 3
TBST washes of 5 minutes each, membranes were in-
cubated with secondary antibody for 2 hours at room
temperature. Membranes were washed again in TBST
(four 10 minute washes) and then developed by enhanced
chemiluminescence (Thermo Scientific) and detected on
X-ray film.
Statistical calculation
Statistical significance was determined using the paired
Student’s t test and a p value ≤ 0.05 to reject the null
hypothesis.
Results
BRAF-mutated papillary thyroid cancer cells are more
susceptible to growth inhibition by PLX4032 in
comparison to normal wild-type thyroid cells
Two thyroid cell lines were chosen to study selective re-
sponse to RAF inhibitor, PLX4032, based on BRAF muta-
tion status. Nthy-ori 3–1 are normal transformed thyroid
cells with wild-type BRAF and BCPAP are papillary thy-
roid cancer cells harboring the BRAFV600E mutation.
Using a XTT cell survival assay with varying concentra-
tions of PLX4032, we observed that cell survival decreased
with increasing doses of PLX4032 and almost total loss of
cell viability occurred at 20 μM PLX4032 in BCPAP cells.
In contrast, at the highest concentration of PLX4032
tested (50 μM), over 25% of Nthy-ori 3–1 cells remained
viable (Figure 1). An IC50 dose of 20 μM was established
Figure 1 Characterization of thyroid cell lines. Nthy-ori3-1 cells are normal, immortalized thyroid cells expressing wild-type BRAF. BCPAP cells
are papillary thyroid cancer cells and are heterozygous for the BRAFV600E mutation. Results of an XTT cell proliferation assay demonstrate percent
of surviving cells after treatment with various concentrations of PLX4032. An IC50 of 10 μM PLX4032 was established for BCPAP cells and an IC50
of 20 μM PLX4032 was established for Nthy-ori3-1 cells.
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our normal thyroid cells are twice as resistant to growth-
inhibiting effects of PLX4032 compared to the more
susceptible BRAF-mutated cancer cells. Based on the IC50
value of PLX4032 for BCPAP cells, 5 μm and 10 μM
PLX4032 were used as investigatory concentrations of
PLX4032 for our experiments.
PLX4032 causes apoptosis selectively in BRAF- mutated
papillary thyroid cancer cells
Multiple cell-based assays were performed to evaluate the
effects of PLX4032 on functional markers of MAPK in-
hibition including proliferation, survival, cell cycle and
apoptosis. To evaluate effects on proliferation and survival
ability, viable cells were counted after a 36 hour treatment
period using a trypan blue exclusion assay. Within BCPAP
cells, PLX4032-treated wells contained significantly fewer
live cells compared to untreated groups, reaching only
about 15% of the number of cells found in untreated
groups (Figure 2a). The Nthy-ori 3–1 cells appeared resis-
tant to PLX4032 in terms of cell proliferation, as the num-
bers of live cells counted in the treatment group were not
changed significantly from numbers counted in the un-
treated wells (Figure 2a). As PLX4032 treatment caused
cell death selectively in BRAFV600E-positive BCPAP cells,
a further experiment to distinguish between apoptotic and
necrotic cell death was conducted. Immunofluorescence
revealed that PLX4032 causes apoptotic cell death rather
than necrotic cell death in BCPAP papillary thyroid cancer
cells and does not appear to contribute to cell death in
non-mutated Nthy-ori 3–1 thyroid cells (Figure 2b).PLX4032 inhibits nucleotide incorporation selectively in
BRAF-mutated papillary thyroid cells
Since PLX4032 has been shown to induce arrest in G1
phase of the cell cycle in BRAF-mutated melanoma cells,
we determined whether this effect also occurred in our
thyroid cell lines. Analysis of cell cycle status in BRAF-
wild-type thyroid cells as well as BRAF-mutated papillary
thyroid cancer cells after treatment with PLX4032 was
performed by directly measuring DNA replication and
assessing cell cycle distribution. In this assay, incorpo-
ration of EdU, the DNA precursor, was measured by laser
scanning cytometry as an indicator of cells actively synthe-
sizing DNA and in S-phase of the cell cycle. PLX4032
treatment diminished EdU uptake in the BCPAP cells and
essentially had no effect on EdU incorporation in normal
thyroid cells (Figure 3). Thus, PLX4032 halts DNA syn-
thesis selectively in the BRAF-mutated papillary thyroid
cancer cells. Furthermore, as evident from the DNA con-
tent frequency histograms, the number of proliferating
cells in S and G2/M phases of the cell cycle was much
lower in the case of BCPAP cells compared to Nthy-ori
3–1 cells. Collectively, these data suggest that PLX4032
exhibits potent anti-proliferative effects in BRAFV600E-
positive thyroid cancer cells.
PLX4032 selectively downregulates phosphorylation of
signaling targets in BRAFV600E-positive thyroid cells
Several groups have demonstrated that mutation-specific
BRAF inhibitors such as PLX4032 will selectively inhibit
MAPK signaling in BRAFV600E-mutated cells and will
activate MAPK signaling in wild-type BRAF cells. To
AB
Figure 2 PLX4032 causes apoptosis selectively in mutated papillary thyroid cancer cells. A) Nthy-ori3-1 and BCPAP cells were plated in
six-well culture dishes in the presence of 10 μM PLX4032 for 36 hours. Viable cells were counted using a trypan blue dye exclusion assay. Asterisks
indicate statistically significant differences (p < .05) between control and treated samples. B) Nthy-ori 3–1 and BCPAP cells were treated with
10 μM PLX4032 for 36 hours and apoptotic and necrotic cells were visualized by immunofluorescence. Red staining is indicative of necrotic cell
death as a result of cellular insult and membrane disruption and green staining marks apoptotic cells that express Annexin V on their outer
membranes. (Blue: Hoechst 33342, Red: Ethidium Homodimer III, green: FITC-Annexin V).
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the MAPK pathway in our thyroid cells, we treated non-
mutated Nthy-ori 3–1 cells and BRAFV600E-positive
BCPAP cells with 5 μM and 10 μM PLX4032 and ana-
lyzed protein expression by western blot. The phos-
phorylation of MEK, MAPK, and mTOR proteins was
inhibited by 10 μM PLX4032 treatment in the mutated
BCPAP cells (Figure 4b). In contrast to the effect seen in
BCPAP cells, PLX4032 treatment of both 5 μM and
10 μM upregulated expression of these phosphorylated
proteins in BRAF-wild-type Nthy-ori 3–1 thyroid cells
(Figure 4a).
Discussion
In the past decade or so, biological discoveries including
the high prevalence and critical role of genetic mutations
in cancer cells have led to the new concept of targeted
molecular therapy. Among potential therapy targets, mu-
tated or overexpressed kinases were recognized early ondue to their ability to enhance tumor-promoting pheno-
types through signal transduction pathways [26]. Small
molecule kinase inhibitors can be designed to be specific
for cancer cells, and, in general, non-cancerous cells are
better able to survive kinase inhibition, allowing for fewer
side effects compared to traditional cytotoxic chemothe-
rapy [27]. However, the heterogenous nature of most can-
cers, the presence of a wild-type gene in addition to the
mutated gene, and the capability to develop resistance to
targeted therapy has posed problems in the field [28].
As mentioned earlier, melanoma patients treated with
PLX4032 developed resistance in about 6–8 months, likely
due to acquisition of new mutations in proteins such as
N-RAS or MEK, overexpression of Receptor Tyrosine Ki-
nases, or activation of alternative signaling pathways
[29,30]. The use of RAF inhibitors such as PLX4032 holds
promise because of its initial effectiveness and selectivity,
and the hope that combinational therapies or earlier de-
tection methods may eliminate resistance problems in the
Figure 3 PLX4032 inhibits incorporation of EdU selectively in mutated papillary thyroid cells. Nthy-ori 3–1 and BCPAP cells were treated
with PLX4032 for 36 hours and then exposed to EdU for 1 hour. The incorporated EdU was detected using the “click chemistry” approach [25],
cellular DNA was counterstained with DAPI and intensity of cellular fluorescence was measured by laser scanning cytometry. The data are shown
as bivariate (DNA content versus EdU incorporation) scatterplot distributions; insets show DNA content frequency histograms from the respective
cultures. Cells positive for EdU were gated and their percentage is shown in the respective panels.
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molecular therapy in thyroid cancer as suggested in earlier
studies, by demonstrating that targeting mutated BRAF
leads to drastic, selective phenotype changes in thyroid
cancer cells in culture [31,32].
Within our mutated BCPAP papillary thyroid cancer
cells, inhibition of BRAFV600E impaired survival ability,
decreased proliferation, caused apoptosis, and halted
DNA synthesis, demonstrating the importance of this sig-
naling molecule in contributing to cancer cell growth.
These marked functional effects of BRAF inhibition likely
occurred as a result of impaired phosphorylation of down-
stream molecules within the MAPK pathway including
phospho-MEK, phospho-MAPK, and phospho-mTOR.
With 10 μM PLX4032 treatment in BCPAP cells we were
able to completely abolish expression of phospho-MAPK,
which is important because a prior clinical study involving
melanoma patients treated with PLX4032 showed that
80% inhibition of phospho-MAPK was required for tumor
regression [33]. The dependence of these papillary thyroid
cancer cells on signaling through the MAPK pathway and
the resulting profound anti-cancer effects by BRAF inhib-
ition can be characterized as “oncogene addiction” [34]
and validate targeting the BRAFV600E mutated protein in
thyroid cancer cells.
In addition to anti-thyroid effects seen with treatment
of the specific RAF inhibitor PLX4032 in BRAF-mutated
cancer cells, we observed paradoxical activation of the
MAPK pathway in BRAF-wild-type Nthy-ori 3–1 thyroid
cells, as previously seen in BRAF-wild-type melanoma
cells [35]. This effect may reflect the nature of the drug, in
that it is capable of binding to wild-type protomers within
CRAF-CRAF or CRAF-BRAF dimers and transactivatingthe associated protomer, and is important in that it
could play a role in drug resistance and toxicity [19-21].
PLX4032-mediated increase in MAPK signaling depends
on upstream signals from RAS which explains why it is
not seen in BRAFV600E mutated cancer cells, however
mutations or overexpression of RAS and other upstream
molecules may allow for PLX4032-mediated MAPK acti-
vation and for acquired resistance by signaling through
wild-type dimers in cancer cells [19-21]. This scenario
could occur in thyroid cancer as both our papillary thyroid
cancer cells and normal thyroid cells express CRAF pro-
tein. It should be noted, however, that this MAPK activa-
tion did not lead to a significant enhancement of cell
proliferation that would be evident by increased DNA rep-
lication or cell cycle status. The presence of paradoxical
MAPK activation in thyroid cells further emphasizes that
selecting thyroid cancer patients for PLX4032 treat-
ment should be dependent on presence of BRAFV600E
mutation.
Overall, the results of this study show that BRAFV600E
is a viable therapy target in thyroid tumors harboring this
specific mutation and in general highlights the potential in
exploiting genetic lesions that lead to overactive signal
transduction. The effects of inhibiting kinase activity of a
single molecule within the MAPK pathway are potent
enough to dramatically and specifically alter papillary thy-
roid carcinoma cellular phenotype, at least in vitro. Within
targeted molecular therapy, searching for mutated kinases
that are associated with poorer prognostic outcomes will
provide targets that can be inhibited with maximal effect.
As seen in melanoma patients, resistance to BRAF inhibi-
tors such as PLX4032 could occur in thyroid cancer pa-
tients as well. To address this, we recommend further
AB
Figure 4 PLX4032 selectively inhibits phosphorylation of signaling targets in BRAFV600E-positive thyroid cells. A) Whole cell protein
was collected from Nthy-ori 3–1 cells that were treated for 24 hours with 5 μM (+) or 10 μM (++) PLX4032. Protein samples (10 μg per lane) were
subjected to SDS-PAGE followed by western blot analysis for MEK (46 kD), p-MEK (45 kD), MAPK (42/44 kD), p-MAPK (42/44 kD), mTOR (289 kD)
and p-mTOR (289 kD). GAPDH (37 kD) was used as a loading control. Quantification of Western blots by densitometry was performed using
ImageJ and bar graphs represent percent expression compared to the untreated. B) BCPAP cells were treated and collected, whole cell lysates
resolved by SDS-PAGE and analyzed by western blot in the same way as Nthy-ori 3–1 cells in A.
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BRAFV600E inhibitors. The exciting, recent success of
a Phase III clinical trial involving Sorafenib, which
caused tumor regression in 12% of patients and signi-
ficantly improved progression-free survival time in pa-
tients with advanced thyroid cancer, supports use of
kinase inhibitors. Sorafenib inhibits the tyrosine kinases
VEGFR and PDGFR in addition to RAF, although it is
more selective for CRAF. Recent studies highlighting
the potential of combination therapy suggest a synergy
between PLX4032 and Akt inhibitors or HER kinase in-
hibitors in thyroid cancer [36,37]. Further investigation
into combination therapy including a specific inhibitor
of BRAFV600E could provide treatment advances for
BRAFV600E-positive advanced thyroid cancer patients.Conclusions
Targeting the specific mutated kinase, BRAFV600E,
within papillary thyroid cancer effectively inhibits growth-
promoting characteristics of papillary thyroid cancer cells
harboring this mutation in vitro by preventing phospho-
rylation of downstream targets and does not have these
effects on normal thyroid cells. Although phenotypic
changes in normal BRAF-wild-type thyroid cells did
not occur upon exposure to the BRAFV600E inhibitor
PLX4032, the drug upregulated phosphorylation of MAPK
proteins downstream of BRAF including phospho-MEK,
phospho-MAPK, and phospho-mTOR. In order to de-
crease possible resistance through wild-type BRAF sig-
naling and other pathways, this study supports further
investigation of combination targeted therapy including a
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positive thyroid cancer patients. Further, we conclude that
PLX4032 should be used only in carefully screened pa-
tients harboring the BRAFV600E mutation.
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